Vijaykumar D. Nimbarte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vijaykumar D. Nimbarte has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Sharda Ishwarkar
Department of Chemistry, Govindrao Wanjari College of Engineering and Technology, Nagpur, 441204, India
3 shared publicationsShreya S. Sonak
Birla Institute of Technology and Science, Pilani, Hyderabad Campus
3 shared publicationsCharu Nimbarte
NCI-National Cancer Institute, Nagpur 441204, India
2 shared publications- Abdelhabib Semlali
GREB Research Group, Faculty of Dentistry, Laval University, Québec, QC G1V 0A6, Canada
1 shared publication - Hawraa Issa
DREAM-CV Lab, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
1 shared publication - Latifa Koussih
Département des Sciences Expérimentales, Université de Saint-Boniface, Winnipeg, MB R2H 3B8, Canada
1 shared publication
Latest Publications
- Open Access
- 17 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 406
Mechanistic Insights into the Anti-Virulence Effects of Viroelixir, a Phenolic Blend from Green Tea and Pomegranate, on Streptococcus mutans
Background: Dental caries remains one of the most prevalent oral diseases worldwide, largely driven by the virulence of Streptococcus mutans. Although plant phenolics from green tea and pomegranate are known for their antimicrobial properties, their molecular mechanisms of action against key S. mutans virulence targets remain insufficiently characterized. Aim: This study investigated the antibacterial and anti-virulence properties of Viroelixir, a phenolic-rich formulation derived from green tea (Camellia sinensis) and pomegranate (Punica granatum), against S. mutans, with particular emphasis on predictive molecular docking interactions with critical virulence-associated proteins. Methods: Viroelixir phytochemical composition was characterized by LC–MS using a C18 reverse-phase column and negative electrospray ionization mode. Antibacterial activity was evaluated using growth kinetics, agar plating, and crystal violet assays. Acidogenicity, hemolytic activity, and biofilm formation were assessed using pH modulation, hemolysis assays, SEM, and biofilm biomass quantification. Virulence gene expression was analyzed by RT-qPCR. In silico molecular docking was performed to explore potential interactions between major LC–MS-supported phenolic constituents and S. mutans virulence proteins, including glucosyltransferase B (GtfB), LuxS, and SpaP. Biocompatibility was evaluated in human gingival epithelial cells. Results: The LC-MS analysis revealed a complex mixture of phenolic compounds consistent with catechins and ellagitannins. Compound identification was considered tentative and based on mass spectral range and chromatographic behavior. Viroelixir significantly inhibited S. mutans growth, acid production, hemolytic activity, and biofilm formation in a concentration-dependent manner. Key virulence genes were markedly downregulated. Docking analyses suggested stable binding of selected phenolics—particularly punicalagin, catechin, and epigallocatechin—within the active sites of GtfB, LuxS, and SpaP. Importantly, Viroelixir showed no cytotoxic effects on gingival epithelial cells. Conclusions: Viroelixir exerts potent antibacterial and anti-virulence effects against S. mutans through a multi-target mechanism combining transcriptional suppression and predictive molecular inhibition of virulence proteins, supporting its potential as a safe, natural therapeutic for caries prevention.
- 17 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 406
Open AccessMechanistic Insights into the Anti-Virulence Effects of Viroelixir, a Phenolic Blend from Green Tea and Pomegranate, on Streptococcus mutans
Background: Dental caries remains one of the most prevalent oral diseases worldwide, largely driven by the virulence of Streptococcus mutans. Although plant phenolics from green tea and pomegranate are known for their antimicrobial properties, their molecular mechanisms of action against key S. mutans virulence targets remain insufficiently characterized. Aim: This study investigated the antibacterial and anti-virulence properties of Viroelixir, a phenolic-rich formulation derived from green tea (Camellia sinensis) and pomegranate (Punica granatum), against S. mutans, with particular emphasis on predictive molecular docking interactions with critical virulence-associated proteins. Methods: Viroelixir phytochemical composition was characterized by LC–MS using a C18 reverse-phase column and negative electrospray ionization mode. Antibacterial activity was evaluated using growth kinetics, agar plating, and crystal violet assays. Acidogenicity, hemolytic activity, and biofilm formation were assessed using pH modulation, hemolysis assays, SEM, and biofilm biomass quantification. Virulence gene expression was analyzed by RT-qPCR. In silico molecular docking was performed to explore potential interactions between major LC–MS-supported phenolic constituents and S. mutans virulence proteins, including glucosyltransferase B (GtfB), LuxS, and SpaP. Biocompatibility was evaluated in human gingival epithelial cells. Results: The LC-MS analysis revealed a complex mixture of phenolic compounds consistent with catechins and ellagitannins. Compound identification was considered tentative and based on mass spectral range and chromatographic behavior. Viroelixir significantly inhibited S. mutans growth, acid production, hemolytic activity, and biofilm formation in a concentration-dependent manner. Key virulence genes were markedly downregulated. Docking analyses suggested stable binding of selected phenolics—particularly punicalagin, catechin, and epigallocatechin—within the active sites of GtfB, LuxS, and SpaP. Importantly, Viroelixir showed no cytotoxic effects on gingival epithelial cells. Conclusions: Viroelixir exerts potent antibacterial and anti-virulence effects against S. mutans through a multi-target mechanism combining transcriptional suppression and predictive molecular inhibition of virulence proteins, supporting its potential as a safe, natural therapeutic for caries prevention.
- 1 January 2026
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 46 (2) , 27-43
Plasmodium Phosphatidylinositol 4-Kinase Beta (PI4Kβ): An Emerging Target at the Interface of Parasite Biology and Host Immunity
Phosphatidylinositol 4-kinase beta (PI4Kβ) is an essential lipid kinase in Plasmodium species, central to intracellular signaling, vesicular trafficking, and parasite development. Recent insights suggest PI4Kβ also plays a key role in modulating host immune responses. Through regulation of protein export, immune evasion mechanisms, and extracellular vesicle formation, PI4Kβ influences the immune landscape during malaria infection. Notably, inhibition of PI4Kβ disrupts parasite survival and may enhance immune recognition by impairing virulence factor trafficking and improving antigen presentation. Targeting PI4Kβ offers a promising dual-action strategy−direct antiplasmodial effects coupled with immunomodulation. This review explores PI4Kβ's emerging role at the interface of parasite survival and host immunity, highlighting its therapeutic potential as both an antiparasitic and immunomodulatory target. Further investigation is warranted to evaluate its role in antigen processing, vaccine responsiveness, and combinatorial immunotherapy. PI4Kβ stands out as a next-generation target for integrated malaria intervention strategies.
- 1 January 2026
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 46 (2) , 27-43
Plasmodium Phosphatidylinositol 4-Kinase Beta (PI4Kβ): An Emerging Target at the Interface of Parasite Biology and Host Immunity
Phosphatidylinositol 4-kinase beta (PI4Kβ) is an essential lipid kinase in Plasmodium species, central to intracellular signaling, vesicular trafficking, and parasite development. Recent insights suggest PI4Kβ also plays a key role in modulating host immune responses. Through regulation of protein export, immune evasion mechanisms, and extracellular vesicle formation, PI4Kβ influences the immune landscape during malaria infection. Notably, inhibition of PI4Kβ disrupts parasite survival and may enhance immune recognition by impairing virulence factor trafficking and improving antigen presentation. Targeting PI4Kβ offers a promising dual-action strategy−direct antiplasmodial effects coupled with immunomodulation. This review explores PI4Kβ's emerging role at the interface of parasite survival and host immunity, highlighting its therapeutic potential as both an antiparasitic and immunomodulatory target. Further investigation is warranted to evaluate its role in antigen processing, vaccine responsiveness, and combinatorial immunotherapy. PI4Kβ stands out as a next-generation target for integrated malaria intervention strategies.
- 1 January 2025
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 45 (5) , 19-34
Modulation of T Cell Regulation by Interleukin-2 Agonists: Mechanisms and Clinical Implications
IL-2 agonists significantly modulate T cell regulation, impacting activation, proliferation, differentiation, and immune homeostasis. Interleukin-2 (IL-2) is crucial for T cell growth and function, binding to the IL-2 receptor to trigger signaling pathways that balance immune responses. IL-2 promotes the expansion of effector T cells and enhances regulatory T cells (Tregs), preventing autoimmune responses. This review examines the mechanisms of IL-2 agonists on T cell regulation, including their roles in cytotoxic T cells and Tregs proliferation, and immune homeostasis. Clinically, IL-2 agonists show promise in treating autoimmune diseases by boosting Treg function and in cancer immunotherapy by enhancing cytotoxic T cell activity. Optimizing IL-2 therapies to balance these effects is ongoing. IL-2 agonists are pivotal in modulating T cell responses with significant therapeutic potential for autoimmunity and cancer. Understanding IL-2 signaling is crucial for developing targeted treatments leveraging this cytokine's benefits.
- 1 January 2025
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 45 (5) , 19-34
Modulation of T Cell Regulation by Interleukin-2 Agonists: Mechanisms and Clinical Implications
IL-2 agonists significantly modulate T cell regulation, impacting activation, proliferation, differentiation, and immune homeostasis. Interleukin-2 (IL-2) is crucial for T cell growth and function, binding to the IL-2 receptor to trigger signaling pathways that balance immune responses. IL-2 promotes the expansion of effector T cells and enhances regulatory T cells (Tregs), preventing autoimmune responses. This review examines the mechanisms of IL-2 agonists on T cell regulation, including their roles in cytotoxic T cells and Tregs proliferation, and immune homeostasis. Clinically, IL-2 agonists show promise in treating autoimmune diseases by boosting Treg function and in cancer immunotherapy by enhancing cytotoxic T cell activity. Optimizing IL-2 therapies to balance these effects is ongoing. IL-2 agonists are pivotal in modulating T cell responses with significant therapeutic potential for autoimmunity and cancer. Understanding IL-2 signaling is crucial for developing targeted treatments leveraging this cytokine's benefits.
- 1 January 2025
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 45 (5) , 49-65
Caseinolytic Protease P: A Therapeutic Nexus in Infection, Inflammation, and Immunity
Caseinolytic protease P (ClpP) is a highly conserved serine protease that plays a pivotal role in protein homeostasis and quality control in bacteria, mitochondria of mammalian cells, and plant chloroplasts. As the proteolytic core of the ATP-dependent Clp protease complex, ClpP partners with regulatory ATPases (e.g., ClpX, ClpA) to degrade misfolded, damaged, or regulatory proteins. In bacteria, ClpP is crucial for survival under host-imposed stresses and modulates virulence through degradation of transcriptional regulators and signaling proteins, contributing to immune evasion, dormancy, and persistence. Particularly in pathogens like Mycobacterium tuberculosis, Staphylococcus aureus, and Listeria monocytogenes, ClpP supports intracellular adaptation and resistance, making it a promising target against antimicrobial-resistant (AMR) infections. In mammalian cells, mitochondrial ClpP ensures oxidative phosphorylation efficiency and regulates innate immunity. Loss of ClpP function can result in mitochondrial dysfunction, triggering immune activation via cytosolic leakage of mitochondrial DNA and subsequent cGAS-STING pathway stimulation. ClpP also influences cytokine production and immune cell differentiation. This dual role of ClpP in pathogen virulence and host immune modulation highlights its potential as an immunotherapeutic target. Pharmacological manipulation of ClpP activity offers novel opportunities for treating infectious diseases, inflammatory conditions, and cancer. Further investigation into ClpP's regulatory mechanisms could inform next-generation host-pathogen intervention strategies.
- 1 January 2025
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 45 (5) , 49-65
Caseinolytic Protease P: A Therapeutic Nexus in Infection, Inflammation, and Immunity
Caseinolytic protease P (ClpP) is a highly conserved serine protease that plays a pivotal role in protein homeostasis and quality control in bacteria, mitochondria of mammalian cells, and plant chloroplasts. As the proteolytic core of the ATP-dependent Clp protease complex, ClpP partners with regulatory ATPases (e.g., ClpX, ClpA) to degrade misfolded, damaged, or regulatory proteins. In bacteria, ClpP is crucial for survival under host-imposed stresses and modulates virulence through degradation of transcriptional regulators and signaling proteins, contributing to immune evasion, dormancy, and persistence. Particularly in pathogens like Mycobacterium tuberculosis, Staphylococcus aureus, and Listeria monocytogenes, ClpP supports intracellular adaptation and resistance, making it a promising target against antimicrobial-resistant (AMR) infections. In mammalian cells, mitochondrial ClpP ensures oxidative phosphorylation efficiency and regulates innate immunity. Loss of ClpP function can result in mitochondrial dysfunction, triggering immune activation via cytosolic leakage of mitochondrial DNA and subsequent cGAS-STING pathway stimulation. ClpP also influences cytokine production and immune cell differentiation. This dual role of ClpP in pathogen virulence and host immune modulation highlights its potential as an immunotherapeutic target. Pharmacological manipulation of ClpP activity offers novel opportunities for treating infectious diseases, inflammatory conditions, and cancer. Further investigation into ClpP's regulatory mechanisms could inform next-generation host-pathogen intervention strategies.